SG11202003944WA - Use of fcrn antagonists for treatment of generalized myasthenia gravis - Google Patents
Use of fcrn antagonists for treatment of generalized myasthenia gravisInfo
- Publication number
- SG11202003944WA SG11202003944WA SG11202003944WA SG11202003944WA SG11202003944WA SG 11202003944W A SG11202003944W A SG 11202003944WA SG 11202003944W A SG11202003944W A SG 11202003944WA SG 11202003944W A SG11202003944W A SG 11202003944WA SG 11202003944W A SG11202003944W A SG 11202003944WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- myasthenia gravis
- generalized myasthenia
- fcrn antagonists
- fcrn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762596562P | 2017-12-08 | 2017-12-08 | |
PCT/EP2018/084034 WO2019110823A1 (en) | 2017-12-08 | 2018-12-07 | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003944WA true SG11202003944WA (en) | 2020-06-29 |
Family
ID=64901981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003944WA SG11202003944WA (en) | 2017-12-08 | 2018-12-07 | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190194277A1 (en) |
EP (1) | EP3720877A1 (en) |
JP (2) | JP7422659B2 (en) |
KR (1) | KR20200096786A (en) |
CN (1) | CN111601820A (en) |
AU (2) | AU2018380979B2 (en) |
BR (1) | BR112020011483A2 (en) |
CA (1) | CA3081144A1 (en) |
EA (1) | EA202091410A1 (en) |
IL (1) | IL274603A (en) |
MA (1) | MA51032A (en) |
MX (1) | MX2020005981A (en) |
SG (1) | SG11202003944WA (en) |
WO (1) | WO2019110823A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI593423B (en) * | 2008-04-25 | 2017-08-01 | 戴埃克斯有限公司 | Fc receptor binding proteins |
SG10202009832XA (en) | 2013-12-24 | 2020-11-27 | Argenx Bvba | Fcrn antagonists and methods of use |
FI3250610T3 (en) | 2015-01-30 | 2023-11-01 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
CA3085751A1 (en) | 2017-12-13 | 2019-06-20 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
JP2022535908A (en) | 2019-06-07 | 2022-08-10 | アルジェニクス ビーブイ | Pharmaceutical Formulations of FcRn Inhibitors Suitable for Subcutaneous Administration |
MX2022001038A (en) * | 2019-07-25 | 2022-04-26 | Genzyme Corp | Methods of treating antibody-mediated disorders with fcrn antagonists. |
WO2022030971A1 (en) | 2020-08-03 | 2022-02-10 | 주식회사 엘지에너지솔루션 | Battery diagnosis device, battery pack, battery system, and battery diagnosis method |
AU2021376364A1 (en) * | 2020-11-06 | 2023-06-22 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
EP4323002A1 (en) * | 2021-04-12 | 2024-02-21 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating pediatric myasthenia gravis |
AU2022322077A1 (en) * | 2021-08-02 | 2024-02-08 | argenx BV | Subcutaneous unit dosage forms |
WO2023242371A1 (en) * | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
WO2024100455A1 (en) | 2022-11-07 | 2024-05-16 | argenx BV | Methods for treating primary membranous nephropathy using fcrn antagonists |
WO2024105445A2 (en) | 2022-11-14 | 2024-05-23 | argenx BV | Fcrn antagonist molecules and methods of use thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1406249B (en) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | Enhancing the circulating half-life of antibody-based fusion proteins |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
EP1562972B1 (en) | 2002-10-15 | 2010-09-08 | Facet Biotech Corporation | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
KR20050110628A (en) * | 2003-02-10 | 2005-11-23 | 엘란 파마슈티칼스, 인크. | Immunoglobulin formulation and method of preparation thereof |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
MX2009012343A (en) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto. |
SG10202009832XA (en) * | 2013-12-24 | 2020-11-27 | Argenx Bvba | Fcrn antagonists and methods of use |
ES2882999T3 (en) * | 2015-03-09 | 2021-12-03 | Argenx Bvba | Methods to Reduce Serum Levels of Fc-Containing Agents Using FcRn Antagonists |
GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
WO2017012959A1 (en) * | 2015-07-17 | 2017-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens |
GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
-
2018
- 2018-12-07 EP EP18829228.8A patent/EP3720877A1/en active Pending
- 2018-12-07 CN CN201880084091.8A patent/CN111601820A/en active Pending
- 2018-12-07 MA MA051032A patent/MA51032A/en unknown
- 2018-12-07 MX MX2020005981A patent/MX2020005981A/en unknown
- 2018-12-07 KR KR1020207018124A patent/KR20200096786A/en active Search and Examination
- 2018-12-07 CA CA3081144A patent/CA3081144A1/en active Pending
- 2018-12-07 US US16/213,422 patent/US20190194277A1/en active Pending
- 2018-12-07 BR BR112020011483-9A patent/BR112020011483A2/en unknown
- 2018-12-07 AU AU2018380979A patent/AU2018380979B2/en active Active
- 2018-12-07 WO PCT/EP2018/084034 patent/WO2019110823A1/en unknown
- 2018-12-07 SG SG11202003944WA patent/SG11202003944WA/en unknown
- 2018-12-07 JP JP2020531031A patent/JP7422659B2/en active Active
- 2018-12-07 EA EA202091410A patent/EA202091410A1/en unknown
-
2020
- 2020-05-12 IL IL274603A patent/IL274603A/en unknown
-
2023
- 2023-09-18 AU AU2023229716A patent/AU2023229716A1/en active Pending
-
2024
- 2024-01-16 JP JP2024004278A patent/JP2024041928A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3720877A1 (en) | 2020-10-14 |
US20190194277A1 (en) | 2019-06-27 |
BR112020011483A2 (en) | 2020-11-24 |
JP7422659B2 (en) | 2024-01-26 |
CN111601820A (en) | 2020-08-28 |
AU2018380979B2 (en) | 2023-07-20 |
MA51032A (en) | 2021-03-17 |
AU2018380979A1 (en) | 2020-05-21 |
EA202091410A1 (en) | 2021-01-13 |
JP2021505603A (en) | 2021-02-18 |
IL274603A (en) | 2020-06-30 |
MX2020005981A (en) | 2020-08-24 |
CA3081144A1 (en) | 2019-06-13 |
KR20200096786A (en) | 2020-08-13 |
JP2024041928A (en) | 2024-03-27 |
AU2023229716A1 (en) | 2023-10-05 |
WO2019110823A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274603A (en) | Use of fcrn antagonists for treatment of generalized myasthenia gravis | |
SG11202001957YA (en) | Methods of direct manipulation of multi-layered user interfaces | |
IL255817B (en) | Synthesis of heterocyclic compounds | |
ZA201905618B (en) | Fused imidazo-piperidine jak inhibitors | |
IL261807A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
GB202009751D0 (en) | Methods of secure communication | |
IL269540A (en) | Purification of phycobiliproteins | |
IL257443A (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
ZA201907834B (en) | New bicyclic pyrazole derivatives | |
IL282137A (en) | Method for the treatment of myasthenia gravis | |
EP3463461A4 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
EP3574907C0 (en) | A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases | |
EP3894768C0 (en) | Methods of cryo-curing | |
HUE063528T2 (en) | Use of anti-cd40 antibodies for treatment of lupus nephritis | |
EP3693360C0 (en) | Heterocyclic compounds | |
PL3449931T3 (en) | Use of cerebrolysin | |
IL267782B (en) | Chemical entities suitable for therapy | |
IL262448B (en) | Substituted bicyclic heterocyclic compounds | |
GB2558700B (en) | 4-substituted Analogs of Cytisine | |
IL263363A (en) | Polymorph of nintedanib | |
PL3728177T3 (en) | Methods of making polyfunctional polyfluorinated compounds | |
GB201604633D0 (en) | Combination of control interfaces for multiple communicating domains | |
GB201810835D0 (en) | Methods of use | |
HK1255406A1 (en) | Anti-sialyl tn chimeric antigen receptors | |
GB201821093D0 (en) | Treatment of hydrocarbons |